Page 113 - MEMORIA ANUAL 2021
P. 113

   MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
  • Coexistence of JAK2V617F mutation and isolated del(5q) in a patient with thrombo- cytosis.
Med Clin (Barc). 2021 Jun 25;156(12):625-7. English, Spanish. doi: 10.1016/j.medc- li.2020.04.065.
Marcé S, Ruiz-Xivillé N, Arenillas L .
• Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Leukemia. 2021 Mar;35(3):835-49. doi: 10.1038/s41375-020-0917-7.
Kuendgen A, Nomdedéu M, Tuechler H, García-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martínez-de-Sola M, Stauder R, Merchán B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedéu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G .
• Different methylation signatures at diagnosis in patients with high-risk myelodys- plastic syndromes and secondary acute myeloid leukemia predict azacitidine re- sponse and longer survival.
Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, García A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group .
• Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modelling GATA2 deficiency.
Stem Cell Res. 2021 Aug;55:102445. doi: 10.1016/j.scr.2021.102445.
Castaño J, Romero-Moya D, Richaud-Patin Y, Giorgetti A .
• Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Ann Hematol. 2021 Aug;100(8):1995-2004. doi: 10.1007/s00277-020-04360-4.
Janusz K, Izquierdo MM, Cadenas FL, Ramos F, Sánchez JMH, Lumbreras E, Robledo C, Del Real JS, Caballero JC, Collado R, Bernal T, Pedro C, Insunza A, de Paz R, Xicoy B, Salido E, Gar- cía JS, Mínguez SS, García CM, Muñoz AMS, Barba MS, Rivas JMH, Abáigar M, Campelo MD .
 113
 














































































   111   112   113   114   115